<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204294</url>
  </required_header>
  <id_info>
    <org_study_id>1218.78</org_study_id>
    <nct_id>NCT01204294</nct_id>
  </id_info>
  <brief_title>Comprehensive Add on Study in Japan</brief_title>
  <official_title>An Open Label, Randomised, Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Background Mono-therapy With an Approved Antidiabetic Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the safety and efficacy of linagliptin
      (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes
      mellitus and insufficient glycaemic control despite diet, exercise, and treatment with one
      approved antidiabetic drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>The first drug administration through 7 days after the last drug administration, up to 382 days</time_frame>
    <description>The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Haemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">574</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Bigu+Lina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>biguanide plus linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glin+Lina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glinide plus linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glit+Lina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glitazone plus linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SU+Lina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sulfonylurea plus linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-GI+Lina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alpha-glucosidase inhibitor plus linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SU+Met</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sulfonylurea plus metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-GI+Met</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>alpha-glucosidase inhibitor plus metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin once daily</description>
    <arm_group_label>Glin+Lina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin once daily</description>
    <arm_group_label>Glit+Lina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin twice or three time per day</description>
    <arm_group_label>A-GI+Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin twice or three time per day</description>
    <arm_group_label>SU+Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin once daily</description>
    <arm_group_label>A-GI+Lina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin once daily</description>
    <arm_group_label>Bigu+Lina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin once daily</description>
    <arm_group_label>SU+Lina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus

          2. Male and female patients on diet and exercise regimen who are treated with one
             antidiabetic drug

        Exclusion criteria:

          1. Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism

          2. Impaired hepatic function

          3. Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined
             as estimated glomerular filtration rate &lt;30 ml/min (severe renal impairment) at Visit
             1, Biguanide group: renal failure or renal impairment defined as estimated glomerular
             filtration rate &lt;60 ml/min (moderate renal impairment) at Visit 1

          4. Treatment with anti-obesity drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.78.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akishima, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amagasaki, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annaka, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aomori, Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aomori, Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashi Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachinaka, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isesaki, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kashiwara, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasugai, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawachinagano, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitaazumi-gun, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meguro-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meguro-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriya, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagae, Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimajiri-gun, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku. Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokorozawa, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokorozawa, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsuchiura, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.78.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamagata, Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <results_first_submitted>December 18, 2012</results_first_submitted>
  <results_first_submitted_qc>December 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2013</results_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 618 patients were enrolled in the trial at 43 trial sites, and 37 patients were withdrawn from the trial because of screening failure. 581 patients were entered into the 2-week placebo run-in period, and 7 patients were withdrawn. 574 patients completed the 2-week placebo run-in period and took linagliptin 5 mg or metformin.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bigu+Lina</title>
          <description>biguanide plus linagliptin</description>
        </group>
        <group group_id="P2">
          <title>Glin+Lina</title>
          <description>glinide plus linagliptin</description>
        </group>
        <group group_id="P3">
          <title>Glit+Lina</title>
          <description>glitazone plus linagliptin</description>
        </group>
        <group group_id="P4">
          <title>SU+Lina</title>
          <description>sulfonylurea plus linagliptin</description>
        </group>
        <group group_id="P5">
          <title>A-GI+Lina</title>
          <description>alpha-glucosidase inhibitor plus linagliptin</description>
        </group>
        <group group_id="P6">
          <title>SU+Met</title>
          <description>sulfonylurea plus metformin</description>
        </group>
        <group group_id="P7">
          <title>A-GI+Met</title>
          <description>alpha-glucosidase inhibitor plus metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="143"/>
                <participants group_id="P5" count="85"/>
                <participants group_id="P6" count="63"/>
                <participants group_id="P7" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="132"/>
                <participants group_id="P5" count="83"/>
                <participants group_id="P6" count="58"/>
                <participants group_id="P7" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (house moving)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bigu+Lina</title>
          <description>biguanide plus linagliptin</description>
        </group>
        <group group_id="B2">
          <title>Glin+Lina</title>
          <description>glinide plus linagliptin</description>
        </group>
        <group group_id="B3">
          <title>Glit+Lina</title>
          <description>glitazone plus linagliptin</description>
        </group>
        <group group_id="B4">
          <title>SU+Lina</title>
          <description>sulfonylurea plus linagliptin</description>
        </group>
        <group group_id="B5">
          <title>A-GI+Lina</title>
          <description>alpha-glucosidase inhibitor plus linagliptin</description>
        </group>
        <group group_id="B6">
          <title>SU+Met</title>
          <description>sulfonylurea plus metformin</description>
        </group>
        <group group_id="B7">
          <title>A-GI+Met</title>
          <description>alpha-glucosidase inhibitor plus metformin</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="143"/>
            <count group_id="B5" value="85"/>
            <count group_id="B6" value="63"/>
            <count group_id="B7" value="61"/>
            <count group_id="B8" value="574"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="9.9"/>
                    <measurement group_id="B2" value="62.6" spread="8.8"/>
                    <measurement group_id="B3" value="60.4" spread="9.4"/>
                    <measurement group_id="B4" value="61.8" spread="10.8"/>
                    <measurement group_id="B5" value="62.0" spread="10.4"/>
                    <measurement group_id="B6" value="61.2" spread="10.6"/>
                    <measurement group_id="B7" value="59.3" spread="10.3"/>
                    <measurement group_id="B8" value="60.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="42"/>
                    <measurement group_id="B8" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events (AEs)</title>
        <description>The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events</description>
        <time_frame>The first drug administration through 7 days after the last drug administration, up to 382 days</time_frame>
        <population>The treated set (TS) comprised all patients who received at least one dose of randomised study medication in the 52-week treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Bigu+Lina</title>
            <description>biguanide plus linagliptin</description>
          </group>
          <group group_id="O2">
            <title>Glin+Lina</title>
            <description>glinide plus linagliptin</description>
          </group>
          <group group_id="O3">
            <title>Glit+Lina</title>
            <description>glitazone plus linagliptin</description>
          </group>
          <group group_id="O4">
            <title>SU+Lina</title>
            <description>sulfonylurea plus linagliptin</description>
          </group>
          <group group_id="O5">
            <title>A-GI+Lina</title>
            <description>alpha-glucosidase inhibitor plus linagliptin</description>
          </group>
          <group group_id="O6">
            <title>SU+Met</title>
            <description>sulfonylurea plus metformin</description>
          </group>
          <group group_id="O7">
            <title>A-GI+Met</title>
            <description>alpha-glucosidase inhibitor plus metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs)</title>
          <description>The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events</description>
          <population>The treated set (TS) comprised all patients who received at least one dose of randomised study medication in the 52-week treatment period</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="143"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="114"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Hypoglycaemic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Haemoglobin A1c (HbA1c)</title>
        <description>The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set (FAS) comprised all treated patients who had baseline HbA1c measurement and at least one on-treatment HbA1c measurement available</population>
        <group_list>
          <group group_id="O1">
            <title>Bigu+Lina</title>
            <description>biguanide plus linagliptin</description>
          </group>
          <group group_id="O2">
            <title>Glin+Lina</title>
            <description>glinide plus linagliptin</description>
          </group>
          <group group_id="O3">
            <title>Glit+Lina</title>
            <description>glitazone plus linagliptin</description>
          </group>
          <group group_id="O4">
            <title>SU+Lina</title>
            <description>sulfonylurea plus linagliptin</description>
          </group>
          <group group_id="O5">
            <title>A-GI+Lina</title>
            <description>alpha-glucosidase inhibitor plus linagliptin</description>
          </group>
          <group group_id="O6">
            <title>SU+Met</title>
            <description>sulfonylurea plus metformin</description>
          </group>
          <group group_id="O7">
            <title>A-GI+Met</title>
            <description>alpha-glucosidase inhibitor plus metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin A1c (HbA1c)</title>
          <description>The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.</description>
          <population>The full analysis set (FAS) comprised all treated patients who had baseline HbA1c measurement and at least one on-treatment HbA1c measurement available</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="62"/>
                <count group_id="O7" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" spread="0.75"/>
                    <measurement group_id="O2" value="7.92" spread="0.82"/>
                    <measurement group_id="O3" value="7.86" spread="0.83"/>
                    <measurement group_id="O4" value="8.12" spread="0.78"/>
                    <measurement group_id="O5" value="7.87" spread="0.75"/>
                    <measurement group_id="O6" value="8.01" spread="0.64"/>
                    <measurement group_id="O7" value="8.07" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="0.82"/>
                    <measurement group_id="O2" value="7.19" spread="0.75"/>
                    <measurement group_id="O3" value="7.07" spread="0.74"/>
                    <measurement group_id="O4" value="7.42" spread="0.91"/>
                    <measurement group_id="O5" value="6.96" spread="0.75"/>
                    <measurement group_id="O6" value="7.19" spread="0.72"/>
                    <measurement group_id="O7" value="6.98" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.64"/>
                    <measurement group_id="O2" value="-0.73" spread="0.65"/>
                    <measurement group_id="O3" value="-0.79" spread="0.50"/>
                    <measurement group_id="O4" value="-0.70" spread="0.70"/>
                    <measurement group_id="O5" value="-0.91" spread="0.61"/>
                    <measurement group_id="O6" value="-0.82" spread="0.78"/>
                    <measurement group_id="O7" value="-1.09" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The first drug administration through 7 days after the last drug administration, up to 382 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bigu+Lina</title>
          <description>biguanide plus linagliptin</description>
        </group>
        <group group_id="E2">
          <title>Glin+Lina</title>
          <description>glinide plus linagliptin</description>
        </group>
        <group group_id="E3">
          <title>Glit+Lina</title>
          <description>glitazone plus linagliptin</description>
        </group>
        <group group_id="E4">
          <title>SU+Lina</title>
          <description>sulfonylurea plus linagliptin</description>
        </group>
        <group group_id="E5">
          <title>A-GI+Lina</title>
          <description>alpha-glucosidase inhibitor plus linagliptin</description>
        </group>
        <group group_id="E6">
          <title>SU+Met</title>
          <description>sulfonylurea plus metformin</description>
        </group>
        <group group_id="E7">
          <title>A-GI+Met</title>
          <description>alpha-glucosidase inhibitor plus metformin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

